25 XP   0   0   10

Plus Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Plus Therapeutics Inc together

PenkeI guess you are interested in Plus Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Plus Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Plus Therapeutics Inc

I send you an email if I find something interesting about Plus Therapeutics Inc.

Quick analysis of Plus Therapeutics Inc (30 sec.)










What can you expect buying and holding a share of Plus Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
15.0%

What is your share worth?

Current worth
$-0.30
Expected worth in 1 year
$-2.08
How sure are you?
42.5%

+ What do you gain per year?

Total Gains per Share
$-1.78
Return On Investment
-102.2%

For what price can you sell your share?

Current Price per Share
$1.74
Expected price per share
$1.37 - $2.26
How sure are you?
50%

1. Valuation of Plus Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

$1.74

Intrinsic Value Per Share

$-11.64 - $5.78

Total Value Per Share

$-11.93 - $5.48

2. Growth of Plus Therapeutics Inc (5 min.)




Is Plus Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?-$1.3m$10.5m-$8.8m-537.8%

How much money is Plus Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$3.3m-$5.2m$1.8m56.5%
Net Profit Margin-394.9%-2,471.2%--

How much money comes from the company's main activities?

3. Financial Health of Plus Therapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#891 / 1019

Most Revenue
#490 / 1019

Most Profit
#363 / 1019

Most Efficient
#721 / 1019

What can you expect buying and holding a share of Plus Therapeutics Inc? (5 min.)

Welcome investor! Plus Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Plus Therapeutics Inc.

What can you expect buying and holding a share of Plus Therapeutics Inc?

First you should know what it really means to hold a share of Plus Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Plus Therapeutics Inc is $1.74. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Plus Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Plus Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.30. Based on the TTM, the Book Value Change Per Share is $-0.44 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.25 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Plus Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.84-48.4%-0.76-43.5%-1.16-66.9%-0.76-43.9%-1.05-60.4%
Usd Book Value Change Per Share-0.90-51.7%-0.44-25.5%-0.25-14.5%-0.07-4.3%-0.03-1.5%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.5431.0%
Usd Total Gains Per Share-0.90-51.7%-0.44-25.5%-0.25-14.5%-0.07-4.3%0.5129.5%
Usd Price Per Share1.75-1.35-0.58-1.53-1.27-
Price to Earnings Ratio-0.52--0.63--0.13--7.07--3.61-
Price-to-Total Gains Ratio-1.94--194.12-0.38--37.74--19.70-
Price to Book Ratio-5.87-0.03-0.23-10.63-5.79-
Price-to-Total Gains Ratio-1.94--194.12-0.38--37.74--19.70-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.74
Number of shares574
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.44-0.07
Usd Total Gains Per Share-0.44-0.07
Gains per Quarter (574 shares)-255.16-42.99
Gains per Year (574 shares)-1,020.62-171.96
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1021-10310-172-182
20-2041-20520-344-354
30-3062-30730-516-526
40-4082-40940-688-698
50-5103-51150-860-870
60-6124-61360-1032-1042
70-7144-71570-1204-1214
80-8165-81780-1376-1386
90-9186-91990-1548-1558
100-10206-102200-1720-1730

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%1.019.00.05.0%3.037.00.07.5%5.087.00.05.4%
Book Value Change Per Share0.04.00.00.0%5.07.00.041.7%9.011.00.045.0%16.024.00.040.0%30.061.01.032.6%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%6.00.034.015.0%15.00.077.016.3%
Total Gains per Share0.04.00.00.0%5.07.00.041.7%9.011.00.045.0%17.023.00.042.5%34.057.01.037.0%

Fundamentals of Plus Therapeutics Inc

About Plus Therapeutics Inc

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead drug candidate is Rhenium-186Re obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

Fundamental data was last updated by Penke on 2024-04-12 15:51:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Plus Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Plus Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Plus Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -290.2% means that $-2.90 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Plus Therapeutics Inc:

  • The MRQ is -290.2%. The company is making a huge loss. -2
  • The TTM is -394.9%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-290.2%TTM-394.9%+104.8%
TTM-394.9%YOY-2,471.2%+2,076.3%
TTM-394.9%5Y-1,044,801.8%+1,044,406.9%
5Y-1,044,801.8%10Y-522,562.4%-522,239.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-290.2%-196.9%-93.3%
TTM-394.9%-211.2%-183.7%
YOY-2,471.2%-279.3%-2,191.9%
5Y-1,044,801.8%-436.8%-1,044,365.0%
10Y-522,562.4%-599.3%-521,963.1%
1.1.2. Return on Assets

Shows how efficient Plus Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Plus Therapeutics Inc to the Biotechnology industry mean.
  • -33.5% Return on Assets means that Plus Therapeutics Inc generated $-0.33 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Plus Therapeutics Inc:

  • The MRQ is -33.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -24.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-33.5%TTM-24.7%-8.7%
TTM-24.7%YOY-22.6%-2.1%
TTM-24.7%5Y-21.2%-3.5%
5Y-21.2%10Y-19.1%-2.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-33.5%-13.6%-19.9%
TTM-24.7%-12.9%-11.8%
YOY-22.6%-11.9%-10.7%
5Y-21.2%-14.2%-7.0%
10Y-19.1%-16.2%-2.9%
1.1.3. Return on Equity

Shows how efficient Plus Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Plus Therapeutics Inc to the Biotechnology industry mean.
  • 0.0% Return on Equity means Plus Therapeutics Inc generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Plus Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-89.5%+89.5%
TTM-89.5%YOY-55.4%-34.1%
TTM-89.5%5Y-94.5%+5.0%
5Y-94.5%10Y-94.0%-0.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--17.0%+17.0%
TTM-89.5%-16.1%-73.4%
YOY-55.4%-15.4%-40.0%
5Y-94.5%-20.0%-74.5%
10Y-94.0%-21.1%-72.9%

1.2. Operating Efficiency of Plus Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Plus Therapeutics Inc is operating .

  • Measures how much profit Plus Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Plus Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of -294.0% means the company generated $-2.94  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Plus Therapeutics Inc:

  • The MRQ is -294.0%. The company is operating very inefficient. -2
  • The TTM is -388.3%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-294.0%TTM-388.3%+94.3%
TTM-388.3%YOY-2,366.4%+1,978.1%
TTM-388.3%5Y-975,071.1%+974,682.8%
5Y-975,071.1%10Y-487,685.1%-487,386.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-294.0%-282.4%-11.6%
TTM-388.3%-225.8%-162.5%
YOY-2,366.4%-288.4%-2,078.0%
5Y-975,071.1%-475.2%-974,595.9%
10Y-487,685.1%-624.7%-487,060.4%
1.2.2. Operating Ratio

Measures how efficient Plus Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 3.94 means that the operating costs are $3.94 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Plus Therapeutics Inc:

  • The MRQ is 3.940. The company is inefficient in keeping operating costs low. -1
  • The TTM is 4.579. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ3.940TTM4.579-0.639
TTM4.579YOY24.656-20.077
TTM4.5795Y9,815.638-9,811.059
5Y9,815.63810Y4,909.804+4,905.834
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.9402.994+0.946
TTM4.5793.247+1.332
YOY24.6563.766+20.890
5Y9,815.6385.675+9,809.963
10Y4,909.8047.857+4,901.947

1.3. Liquidity of Plus Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Plus Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.92 means the company has $0.92 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Plus Therapeutics Inc:

  • The MRQ is 0.917. The company is just not able to pay all its short-term debts. -1
  • The TTM is 1.041. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ0.917TTM1.041-0.125
TTM1.041YOY2.964-1.923
TTM1.0415Y1.693-0.652
5Y1.69310Y1.548+0.145
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9173.930-3.013
TTM1.0414.251-3.210
YOY2.9645.436-2.472
5Y1.6936.045-4.352
10Y1.5486.383-4.835
1.3.2. Quick Ratio

Measures if Plus Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Plus Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 0.80 means the company can pay off $0.80 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Plus Therapeutics Inc:

  • The MRQ is 0.797. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.966. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.797TTM0.966-0.168
TTM0.966YOY2.795-1.829
TTM0.9665Y1.583-0.617
5Y1.58310Y1.292+0.291
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7973.629-2.832
TTM0.9664.065-3.099
YOY2.7955.390-2.595
5Y1.5835.993-4.410
10Y1.2926.277-4.985

1.4. Solvency of Plus Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Plus Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Plus Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.12 means that Plus Therapeutics Inc assets are financed with 111.8% credit (debt) and the remaining percentage (100% - 111.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Plus Therapeutics Inc:

  • The MRQ is 1.118. The company is just not able to pay all its debts by selling its assets. -1
  • The TTM is 0.891. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ1.118TTM0.891+0.228
TTM0.891YOY0.546+0.345
TTM0.8915Y0.767+0.123
5Y0.76710Y0.800-0.033
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1180.332+0.786
TTM0.8910.333+0.558
YOY0.5460.268+0.278
5Y0.7670.366+0.401
10Y0.8000.390+0.410
1.4.2. Debt to Equity Ratio

Measures if Plus Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Plus Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Plus Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM3.310-3.310
TTM3.310YOY1.400+1.910
TTM3.3105Y23.083-19.773
5Y23.08310Y14.177+8.906
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.380-0.380
TTM3.3100.389+2.921
YOY1.4000.334+1.066
5Y23.0830.432+22.651
10Y14.1770.465+13.712

2. Market Valuation of Plus Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Plus Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Plus Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -0.52 means the investor is paying $-0.52 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Plus Therapeutics Inc:

  • The EOD is -0.516. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.519. Based on the earnings, the company is expensive. -2
  • The TTM is -0.631. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.516MRQ-0.519+0.003
MRQ-0.519TTM-0.631+0.111
TTM-0.631YOY-0.133-0.498
TTM-0.6315Y-7.067+6.437
5Y-7.06710Y-3.606-3.461
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.516-2.426+1.910
MRQ-0.519-2.552+2.033
TTM-0.631-2.656+2.025
YOY-0.133-4.143+4.010
5Y-7.067-6.252-0.815
10Y-3.606-6.108+2.502
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Plus Therapeutics Inc:

  • The EOD is -1.023. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.029. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.619. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.023MRQ-1.029+0.006
MRQ-1.029TTM-0.619-0.410
TTM-0.619YOY-0.182-0.438
TTM-0.6195Y-0.519-0.100
5Y-0.51910Y-0.365-0.154
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.023-3.199+2.176
MRQ-1.029-3.259+2.230
TTM-0.619-3.552+2.933
YOY-0.182-5.617+5.435
5Y-0.519-8.326+7.807
10Y-0.365-8.689+8.324
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Plus Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -5.87 means the investor is paying $-5.87 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Plus Therapeutics Inc:

  • The EOD is -5.838. Based on the equity, the company is expensive. -2
  • The MRQ is -5.871. Based on the equity, the company is expensive. -2
  • The TTM is 0.033. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD-5.838MRQ-5.871+0.034
MRQ-5.871TTM0.033-5.904
TTM0.033YOY0.232-0.199
TTM0.0335Y10.628-10.595
5Y10.62810Y5.792+4.836
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-5.8381.947-7.785
MRQ-5.8712.116-7.987
TTM0.0332.095-2.062
YOY0.2322.836-2.604
5Y10.6283.443+7.185
10Y5.7923.791+2.001
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Plus Therapeutics Inc.

3.1. Institutions holding Plus Therapeutics Inc

Institutions are holding 3.272% of the shares of Plus Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Renaissance Technologies Corp0.72970.000133000330000
2023-09-30Geode Capital Management, LLC0.5869026543953656.071
2023-09-30Millennium Management LLC0.4367019749197490
2023-09-30Vanguard Group Inc0.3581016197-56664-77.77
2023-09-30HRT FINANCIAL LLC0.24830.000211232112320
2023-12-31BlackRock Inc0.15390696000
2023-09-30UBS Group AG0.11380514951490
2023-09-30Tower Research Capital LLC0.03210.00011451-3280-69.33
2023-09-30Citigroup Inc0.012805795790
2023-09-30Advisor Group Holdings, Inc.0.0029013300
2023-09-30Wells Fargo & Co0.0005021316.6667
2023-09-30JPMorgan Chase & Co00220
2023-09-30Group One Trading, LP00100
Total 2.67570.0004121017+19306+16.0%

3.2. Funds holding Plus Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.74730.00013254100
2024-02-29Fidelity Extended Market Index0.35880.000115624-76-0.4841
2024-02-29Fidelity Nasdaq Composite Index0.20440.0001889900
2024-02-29Fidelity Series Total Market Index0.0910396400
2023-12-31NT Ext Equity Mkt Idx Fd - L0.05360.0001233200
2023-12-31Northern Trust Extended Eq Market Idx0.05360.0001233200
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.03310144100
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.02660115720.1732
2024-02-29Spartan Total Market Index Pool E0.0161070000
2024-03-31State St US Extended Mkt Indx NL Cl C0.01520.000166300
2023-12-31SSgA U.S. Extended Market Index Class I0.0152066300
2023-12-31SSgA U.S. Total Market Index Strategy0.00440191-4-2.0513
2024-02-29Spartan Extended Market Index Pool E0.0017076760
2023-12-31Northern Trust Wilshire 50000.001506400
2023-12-31NT US Market Cap Idx Fd - L0.001506400
2023-12-31NT Ext Eq Mkt Indx Fd DC Lending Tier 50.001104700
2024-03-31BlackRock Extended Equity Market K0.00010300
2023-09-30BlackRock Extended Mkt Composite0.00010300
2024-03-31Extended Equity Market Fund M00100
Total 1.62530.000670765-20.0%

3.3. Insider Transactions

Insiders are holding 1.45% of the shares of Plus Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-11-20Marc H HedrickSELL20681.96
2023-11-15Robert P LenkBUY10001.77
2023-11-13Robert P LenkBUY40001.43
2023-11-10Robert P LenkBUY20001.45
2023-11-08Robert P LenkBUY50001.65
2023-11-06Robert P LenkBUY13951.5
2023-09-13Howard ClowesBUY69931.43
2023-09-11Greg PetersenBUY200001.7
2023-06-06Howard ClowesBUY10003.98
2023-05-03Howard ClowesBUY25003.64

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Plus Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.900-0.445-51%-0.252-72%-0.075-92%-0.025-97%
Book Value Per Share---0.2980.382-178%2.421-112%1.192-125%1.205-125%
Current Ratio--0.9171.041-12%2.964-69%1.693-46%1.548-41%
Debt To Asset Ratio--1.1180.891+26%0.546+105%0.767+46%0.800+40%
Debt To Equity Ratio---3.310-100%1.400-100%23.083-100%14.177-100%
Dividend Per Share----0%-0%-0%0.539-100%
Eps---0.842-0.756-10%-1.164+38%-0.764-9%-1.051+25%
Free Cash Flow Per Share---0.425-0.743+75%-0.788+85%-0.597+40%-0.894+110%
Free Cash Flow To Equity Per Share---0.542-0.544+0%-0.016-97%-0.027-95%-0.074-86%
Gross Profit Margin--1.0481.012+4%1.000+5%1.007+4%1.063-1%
Intrinsic Value_10Y_max--5.779--------
Intrinsic Value_10Y_min---11.636--------
Intrinsic Value_1Y_max---2.348--------
Intrinsic Value_1Y_min---3.188--------
Intrinsic Value_3Y_max---4.824--------
Intrinsic Value_3Y_min---7.884--------
Intrinsic Value_5Y_max---4.610--------
Intrinsic Value_5Y_min---10.687--------
Market Cap7577073.600-4%7914648.0005952271.000+33%2514804.600+215%6662059.360+19%5527945.560+43%
Net Profit Margin---2.902-3.949+36%-24.712+752%-10448.018+359959%-5225.624+179985%
Operating Margin---2.940-3.883+32%-23.664+705%-9750.711+331576%-4876.851+165789%
Operating Ratio--3.9404.579-14%24.656-84%9815.638-100%4909.804-100%
Pb Ratio-5.838+1%-5.8710.033-18108%0.232-2630%10.628-155%5.792-201%
Pe Ratio-0.516+1%-0.519-0.631+21%-0.133-74%-7.067+1261%-3.606+594%
Price Per Share1.740-1%1.7501.350+30%0.578+203%1.527+15%1.268+38%
Price To Free Cash Flow Ratio-1.023+1%-1.029-0.619-40%-0.182-82%-0.519-50%-0.365-65%
Price To Total Gains Ratio-1.933+1%-1.944-194.118+9885%0.381-610%-37.742+1841%-19.704+914%
Quick Ratio--0.7970.966-17%2.795-71%1.583-50%1.292-38%
Return On Assets---0.335-0.247-26%-0.226-32%-0.212-37%-0.191-43%
Return On Equity----0.8950%-0.5540%-0.9450%-0.9400%
Total Gains Per Share---0.900-0.445-51%-0.252-72%-0.075-92%0.513-275%
Usd Book Value---1348000.0001653000.000-182%10542500.000-113%5188450.000-126%5244150.000-126%
Usd Book Value Change Per Share---0.900-0.445-51%-0.252-72%-0.075-92%-0.025-97%
Usd Book Value Per Share---0.2980.382-178%2.421-112%1.192-125%1.205-125%
Usd Dividend Per Share----0%-0%-0%0.539-100%
Usd Eps---0.842-0.756-10%-1.164+38%-0.764-9%-1.051+25%
Usd Free Cash Flow---1923000.000-3252750.000+69%-3432750.000+79%-2603300.000+35%-3895975.000+103%
Usd Free Cash Flow Per Share---0.425-0.743+75%-0.788+85%-0.597+40%-0.894+110%
Usd Free Cash Flow To Equity Per Share---0.542-0.544+0%-0.016-97%-0.027-95%-0.074-86%
Usd Market Cap7577073.600-4%7914648.0005952271.000+33%2514804.600+215%6662059.360+19%5527945.560+43%
Usd Price Per Share1.740-1%1.7501.350+30%0.578+203%1.527+15%1.268+38%
Usd Profit---3810000.000-3329500.000-13%-5209500.000+37%-3334150.000-12%-4503875.000+18%
Usd Revenue--1313000.0001228250.000+7%74250.000+1668%660774.350+99%1422937.175-8%
Usd Total Gains Per Share---0.900-0.445-51%-0.252-72%-0.075-92%0.513-275%
 EOD+2 -6MRQTTM+17 -16YOY+18 -155Y+15 -1810Y+16 -19

4.2. Fundamental Score

Let's check the fundamental score of Plus Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.516
Price to Book Ratio (EOD)Between0-1-5.838
Net Profit Margin (MRQ)Greater than0-2.902
Operating Margin (MRQ)Greater than0-2.940
Quick Ratio (MRQ)Greater than10.797
Current Ratio (MRQ)Greater than10.917
Debt to Asset Ratio (MRQ)Less than11.118
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.335
Total1/10 (10.0%)

4.3. Technical Score

Let's check the technical score of Plus Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5041.164
Ma 20Greater thanMa 501.849
Ma 50Greater thanMa 1001.885
Ma 100Greater thanMa 2001.915
OpenGreater thanClose1.820
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Total Stockholder Equity 6,445-3,7692,676-142,662-402,622-3,970-1,348
Net Working Capital  9,965-9,132833132965811,046-1,939-893



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets11,388
Total Liabilities12,736
Total Stockholder Equity-1,348
 As reported
Total Liabilities 12,736
Total Stockholder Equity+ -1,348
Total Assets = 11,388

Assets

Total Assets11,388
Total Current Assets9,834
Long-term Assets1,554
Total Current Assets
Cash And Cash Equivalents 8,554
Other Current Assets 1,280
Total Current Assets  (as reported)9,834
Total Current Assets  (calculated)9,834
+/-0
Long-term Assets
Property Plant Equipment 1,108
Goodwill 372
Intangible Assets 42
Long-term Assets Other 32
Long-term Assets  (as reported)1,554
Long-term Assets  (calculated)1,554
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities10,727
Long-term Liabilities2,009
Total Stockholder Equity-1,348
Total Current Liabilities
Short-term Debt 4,096
Short Long Term Debt 3,976
Accounts payable 4,758
Other Current Liabilities 1,873
Total Current Liabilities  (as reported)10,727
Total Current Liabilities  (calculated)14,703
+/- 3,976
Long-term Liabilities
Capital Lease Obligations 205
Long-term Liabilities  (as reported)2,009
Long-term Liabilities  (calculated)205
+/- 1,804
Total Stockholder Equity
Common Stock5
Retained Earnings -480,501
Other Stockholders Equity 479,148
Total Stockholder Equity (as reported)-1,348
Total Stockholder Equity (calculated)-1,348
+/-0
Other
Capital Stock5
Cash and Short Term Investments 8,554
Common Stock Shares Outstanding 4,523
Liabilities and Stockholders Equity 11,388
Net Debt -4,373
Net Invested Capital 2,628
Net Working Capital -893
Property Plant and Equipment Gross 3,644
Short Long Term Debt Total 4,181



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-302002-03-312001-12-312001-09-302001-06-302001-03-31
> Total Assets 
51,360
47,254
44,563
43,143
39,772
36,032
40,254
39,319
34,832
32,620
32,252
28,089
28,550
30,965
30,002
25,470
20,751
26,413
21,157
28,166
32,595
22,434
30,855
24,868
24,868
36,811
28,949
21,507
18,380
16,930
26,668
25,609
27,658
25,682
25,001
24,749
35,445
50,486
43,377
66,347
57,241
48,756
55,568
51,534
49,102
40,504
32,010
43,250
33,366
39,764
35,222
42,060
39,422
38,250
32,314
38,719
37,046
46,524
42,446
37,698
32,915
42,680
36,842
34,609
29,771
32,476
26,446
31,615
26,642
22,677
25,532
23,991
24,616
8,884
25,715
23,229
20,967
13,904
11,653
12,105
18,336
20,834
24,750
21,981
24,516
21,271
23,104
23,867
15,638
14,197
13,278
11,388
11,38813,27814,19715,63823,86723,10421,27124,51621,98124,75020,83418,33612,10511,65313,90420,96723,22925,7158,88424,61623,99125,53222,67726,64231,61526,44632,47629,77134,60936,84242,68032,91537,69842,44646,52437,04638,71932,31438,25039,42242,06035,22239,76433,36643,25032,01040,50449,10251,53455,56848,75657,24166,34743,37750,48635,44524,74925,00125,68227,65825,60926,66816,93018,38021,50728,94936,81124,86824,86830,85522,43432,59528,16621,15726,41320,75125,47030,00230,96528,55028,08932,25232,62034,83239,31940,25436,03239,77243,14344,56347,25451,360
   > Total Current Assets 
46,560
40,800
38,150
36,950
33,192
29,484
35,008
28,214
23,802
21,511
21,353
16,916
17,541
20,558
19,804
15,645
11,092
16,746
11,488
17,540
20,257
10,680
19,543
13,978
13,978
27,304
19,752
12,238
9,298
8,074
18,107
17,225
19,700
18,323
18,005
18,098
28,925
43,809
36,432
58,953
48,937
40,430
47,625
43,337
40,333
31,977
23,592
33,979
24,200
21,719
18,093
24,577
22,052
20,540
14,646
21,686
19,861
29,657
26,030
21,243
16,515
26,750
21,041
18,747
12,085
15,623
9,842
14,864
10,736
7,362
10,754
9,648
8,462
5,260
22,264
19,825
17,697
10,793
8,649
9,175
15,446
18,001
22,097
19,724
22,104
18,889
20,879
21,817
13,629
12,364
11,584
9,834
9,83411,58412,36413,62921,81720,87918,88922,10419,72422,09718,00115,4469,1758,64910,79317,69719,82522,2645,2608,4629,64810,7547,36210,73614,8649,84215,62312,08518,74721,04126,75016,51521,24326,03029,65719,86121,68614,64620,54022,05224,57718,09321,71924,20033,97923,59231,97740,33343,33747,62540,43048,93758,95336,43243,80928,92518,09818,00518,32319,70017,22518,1078,0749,29812,23819,75227,30413,97813,97819,54310,68020,25717,54011,48816,74611,09215,64519,80420,55817,54116,91621,35321,51123,80228,21435,00829,48433,19236,95038,15040,80046,560
       Cash And Cash Equivalents 
7,300
2,725
2,787
2,700
3,568
3,449
4,302
5,108
2,543
2,088
2,349
2,820
3,371
2,093
2,986
2,840
864
3,076
2,275
8,007
6,986
2,379
13,615
8,902
8,902
22,808
17,939
11,465
8,010
5,328
13,387
12,611
15,472
13,920
13,140
12,854
22,684
38,100
30,729
52,668
42,647
33,229
40,803
36,922
34,399
25,771
17,628
25,717
16,404
13,621
10,205
15,506
12,800
12,760
7,849
14,622
13,199
23,842
18,970
14,338
9,358
20,042
14,924
12,560
6,255
9,028
4,783
9,550
5,902
3,079
6,806
5,261
3,872
4,530
16,834
17,552
16,061
9,266
7,626
8,346
14,447
17,161
21,280
18,400
21,239
18,090
20,266
18,120
12,723
10,895
11,006
8,554
8,55411,00610,89512,72318,12020,26618,09021,23918,40021,28017,16114,4478,3467,6269,26616,06117,55216,8344,5303,8725,2616,8063,0795,9029,5504,7839,0286,25512,56014,92420,0429,35814,33818,97023,84213,19914,6227,84912,76012,80015,50610,20513,62116,40425,71717,62825,77134,39936,92240,80333,22942,64752,66830,72938,10022,68412,85413,14013,92015,47212,61113,3875,3288,01011,46517,93922,8088,9028,90213,6152,3796,9868,0072,2753,0768642,8402,9862,0933,3712,8202,3492,0882,5435,1084,3023,4493,5682,7002,7872,7257,300
       Short-term Investments 
34,240
34,105
31,054
31,251
26,608
21,528
17,432
19,875
17,960
16,608
14,540
11,448
11,762
15,940
13,991
10,579
7,301
11,746
7,284
7,838
10,253
6,964
4,834
3,976
3,976
3,795
994
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000000000000000000000000000000009943,7953,9763,9764,8346,96410,2537,8387,28411,7467,30110,57913,99115,94011,76211,44814,54016,60817,96019,87517,43221,52826,60831,25131,05434,10534,240
       Net Receivables 
1,200
617
877
463
282
1,775
11,527
1,238
1,467
1,186
2,823
1,291
1,001
1,457
178
863
1,660
491
997
816
1,983
344
161
288
288
45
31
75
146
1,073
2,231
1,621
1,219
1,504
1,855
1,631
2,689
2,573
1,664
2,073
1,774
2,461
1,967
2,260
1,425
1,983
1,463
3,926
2,961
2,897
2,622
4,152
3,636
2,004
532
1,243
704
750
1,134
1,052
829
911
918
1,242
873
807
230
257
769
399
440
377
455
80
4,781
1,313
978
951
0
59
0
0
0
7
0
0
73
0
0
718
91
0
09171800730070005909519781,3134,781804553774403997692572308078731,2429189118291,0521,1347507041,2435322,0043,6364,1522,6222,8972,9613,9261,4631,9831,4252,2601,9672,4611,7742,0731,6642,5732,6891,6311,8551,5041,2191,6212,2311,0731467531452882881613441,9838169974911,6608631781,4571,0011,2912,8231,1861,4671,23811,5271,7752824638776171,200
       Inventory 
2,810
2,325
2,419
1,685
1,942
2,162
900
1,150
1,148
1,054
987
831
856
463
459
379
533
532
262
258
223
202
210
164
164
92
0
0
360
932
1,436
2,143
1,851
1,861
1,894
2,589
2,603
2,555
3,065
3,378
3,552
3,891
4,153
3,318
3,374
3,108
3,411
3,175
3,646
4,012
4,138
3,694
4,225
4,488
5,020
4,829
4,614
4,079
4,612
4,298
4,462
4,534
3,946
3,725
4,107
4,243
3,508
3,183
3,188
3,007
2,814
2,947
3,003
107
107
107
107
107
107
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000001071071071071071073,0032,9472,8143,0073,1883,1833,5084,2434,1073,7253,9464,5344,4624,2984,6124,0794,6144,8295,0204,4884,2253,6944,1384,0123,6463,1753,4113,1083,3743,3184,1533,8913,5523,3783,0652,5552,6032,5891,8941,8611,8512,1431,43693236000921641642102022232582625325333794594638568319871,0541,1481,1509002,1621,9421,6852,4192,3252,810
       Other Current Assets 
1,010
1,028
1,013
851
792
570
847
843
684
575
654
526
551
605
2,190
984
734
901
670
621
812
791
2
0
648
564
788
698
782
741
1,053
252
1,158
1,038
1,116
1,024
949
581
974
834
964
849
702
837
1,135
1,115
1,090
1,161
1,189
1,189
1,128
1,225
1,391
1,288
1,245
992
1,344
986
1,314
1,555
1,866
1,263
1,253
870
500
1,116
892
1,874
837
837
654
1,063
1,092
503
502
853
551
469
916
770
999
840
817
1,317
865
799
540
3,697
906
751
487
1,280
1,2804877519063,6975407998651,3178178409997709164695518535025031,0921,0636548378371,8748921,1165008701,2531,2631,8661,5551,3149861,3449921,2451,2881,3911,2251,1281,1891,1891,1611,0901,1151,1358377028499648349745819491,0241,1161,0381,1582521,053741782698788564648027918126216709017349842,1906055515266545756848438475707928511,0131,0281,010
   > Long-term Assets 
4,800
6,454
6,413
6,193
6,580
6,548
5,246
11,105
11,030
11,109
10,899
11,173
11,009
10,407
10,198
9,825
9,659
9,667
9,669
10,626
12,338
11,754
11,312
0
10,890
9,507
9,197
9,269
9,082
8,856
8,561
8,384
7,958
7,359
6,996
6,651
6,520
6,677
6,945
7,394
8,304
8,326
7,943
8,197
8,769
8,527
8,418
9,271
9,166
18,045
17,129
17,483
17,370
17,710
17,668
17,033
17,185
16,867
16,416
16,455
16,400
15,930
15,801
15,862
17,686
16,853
16,604
16,751
15,906
15,315
14,778
14,343
16,154
3,624
3,451
3,404
3,270
3,111
3,004
2,930
2,890
2,833
2,653
2,257
2,412
2,382
2,225
2,050
2,009
1,833
1,694
1,554
1,5541,6941,8332,0092,0502,2252,3822,4122,2572,6532,8332,8902,9303,0043,1113,2703,4043,4513,62416,15414,34314,77815,31515,90616,75116,60416,85317,68615,86215,80115,93016,40016,45516,41616,86717,18517,03317,66817,71017,37017,48317,12918,0459,1669,2718,4188,5278,7698,1977,9438,3268,3047,3946,9456,6776,5206,6516,9967,3597,9588,3848,5618,8569,0829,2699,1979,50710,890011,31211,75412,33810,6269,6699,6679,6599,82510,19810,40711,00911,17310,89911,10911,03011,1055,2466,5486,5806,1936,4136,4544,800
       Property Plant Equipment 
4,660
5,321
5,333
5,171
5,191
5,209
3,664
3,626
3,575
3,471
3,680
3,822
3,765
3,554
3,396
3,080
2,917
2,900
3,044
4,260
5,910
5,351
4,578
4,242
4,242
3,897
3,639
3,432
3,270
3,062
2,820
2,552
2,278
1,812
1,547
1,314
1,287
1,220
1,172
1,684
1,773
1,923
1,788
1,711
2,367
2,255
2,242
2,174
2,049
2,043
1,550
1,054
1,192
1,290
1,571
1,583
1,778
1,860
1,734
1,631
1,523
1,380
1,292
1,157
3,611
3,387
3,308
3,052
2,907
2,763
2,648
2,559
4,760
3,202
3,027
2,960
2,840
2,721
2,614
2,456
2,425
2,376
2,205
1,818
1,874
1,863
1,728
1,572
1,546
1,385
1,241
1,108
1,1081,2411,3851,5461,5721,7281,8631,8741,8182,2052,3762,4252,4562,6142,7212,8402,9603,0273,2024,7602,5592,6482,7632,9073,0523,3083,3873,6111,1571,2921,3801,5231,6311,7341,8601,7781,5831,5711,2901,1921,0541,5502,0432,0492,1742,2422,2552,3671,7111,7881,9231,7731,6841,1721,2201,2871,3141,5471,8122,2782,5522,8203,0623,2703,4323,6393,8974,2424,2424,5785,3515,9104,2603,0442,9002,9173,0803,3963,5543,7653,8223,6803,4713,5753,6263,6645,2095,1915,1715,3335,3214,660
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
4,627
4,627
4,387
4,387
4,387,000
4,387
4,387
4,387
4,387,000
4,387
4,387
4,387
4,387
4,387
3,922
3,922
3,922
3,922
3,922
3,922
3,922
3,922
3,922
3,922
3,922
3,922
3,922
3,922
3,922
3,922
3,922
3,922
3,922
3,922
3,922
3,922
3,922
3,922
3,922
3,922
3,922
3,922
3,922
3,922
3,922
3,922
3,922
3,922
3,922
3,922
3,922
3,922
3,922
3,922
3,922
3,922
3,922
3,922
3,922
3,922
3,922
3,922
372
372
372
372
372
372
372
372
372
372
372
372
372
372
372
372
372
372
372
3723723723723723723723723723723723723723723723723723723723,9223,9223,9223,9223,9223,9223,9223,9223,9223,9223,9223,9223,9223,9223,9223,9223,9223,9223,9223,9223,9223,9223,9223,9223,9223,9223,9223,9223,9223,9223,9223,9223,9223,9223,9223,9223,9223,9223,9223,9223,9223,9223,9223,9223,9223,9223,9223,9224,3874,3874,3874,3874,3874,387,0004,3874,3874,3874,387,0004,3874,3874,6274,62700000000000
       Intangible Assets 
0
0
0
0
0
0
0
6,917
6,917
0
7,086
2,392
2,324
2,257
2,189
6,509
6,442
6,374
6,307
5,908
1,466
1,411
1,355
1,300
1,300
1,189
1,134
1,078
1,023
967
912
857
801
746
690
635
580
524
469
413
358
303
247
192
136
81
26
0
0
9,282
9,345
9,345
9,494
9,581
9,534
9,415
9,350
9,255
9,196
9,031
8,923
8,829
8,763
8,447
8,145
7,832
7,520
7,207
6,895
6,582
6,270
5,957
5,645
0
0
0
0
0
0
86
77
69
60
51
150
131
113
94
79
64
49
42
424964799411313115051606977860000005,6455,9576,2706,5826,8957,2077,5207,8328,1458,4478,7638,8298,9239,0319,1969,2559,3509,4159,5349,5819,4949,3459,3459,2820026811361922473033584134695245806356907468018579129671,0231,0781,1341,1891,3001,3001,3551,4111,4665,9086,3076,3746,4426,5092,1892,2572,3242,3927,08606,9176,9170000000
       Long-term Assets Other 
140
1,133
1,080
1,022
1,389
1,339
1,582
562
559
443
133
332
293
209
226
236
300
393
318
458
575
605
992
961
961
499
502
837
867
905
907
1,053
649
582
548
500
472
456
870
916
1,838
1,821
1,680
2,122
2,144
2,105
2,106
3,090
3,158
2,798
2,312
3,162
2,762
2,917
2,641
2,113
2,135
1,830
1,564
1,871
2,032
1,799
1,824
2,336
2,008
1,712
1,854
2,570
2,182
2,048
1,938
1,905
1,827
50
52
72
58
18
18
16
16
16
16
16
16
16
12
12
12
12
32
32
323212121212161616161616161818587252501,8271,9051,9382,0482,1822,5701,8541,7122,0082,3361,8241,7992,0321,8711,5641,8302,1352,1132,6412,9172,7623,1622,3122,7983,1583,0902,1062,1052,1442,1221,6801,8211,8389168704564725005485826491,0539079058678375024999619619926055754583183933002362262092933321334435595621,5821,3391,3891,0221,0801,133140
> Total Liabilities 
2,920
2,789
2,659
4,657
4,524
4,276
12,678
13,324
12,140
11,821
13,283
13,180
12,155
18,348
12,839
12,637
12,444
20,371
16,875
34,395
44,984
40,931
40,814
35,681
35,681
32,311
28,711
30,907
29,444
29,128
28,981
33,326
33,381
26,562
26,424
28,407
22,707
36,386
38,859
43,474
44,885
38,615
43,642
41,588
42,252
39,956
41,742
36,795
30,998
38,501
38,410
38,928
37,020
37,057
35,607
44,421
60,241
44,264
37,446
25,492
25,172
23,959
23,172
23,623
22,408
21,246
18,627
18,615
18,162
17,926
19,394
18,766
20,759
15,160
25,555
22,069
20,882
10,604
9,032
9,074
8,823
8,889
9,995
11,145
9,874
11,592
11,700
17,422
12,962
11,535
10,656
12,736
12,73610,65611,53512,96217,42211,70011,5929,87411,1459,9958,8898,8239,0749,03210,60420,88222,06925,55515,16020,75918,76619,39417,92618,16218,61518,62721,24622,40823,62323,17223,95925,17225,49237,44644,26460,24144,42135,60737,05737,02038,92838,41038,50130,99836,79541,74239,95642,25241,58843,64238,61544,88543,47438,85936,38622,70728,40726,42426,56233,38133,32628,98129,12829,44430,90728,71132,31135,68135,68140,81440,93144,98434,39516,87520,37112,44412,63712,83918,34812,15513,18013,28311,82112,14013,32412,6784,2764,5244,6572,6592,7892,920
   > Total Current Liabilities 
1,570
1,542
1,517
1,831
1,897
1,901
2,706
2,912
2,211
2,420
4,211
4,484
3,322
3,313
3,206
3,267
3,235
3,262
4,664
7,081
6,483
5,200
5,736
6,586
6,586
5,598
5,593
8,070
7,308
7,320
6,997
7,135
6,892
6,476
6,633
8,183
7,112
7,229
9,617
13,223
14,640
15,612
6,443
7,821
10,957
12,404
15,355
17,613
16,684
7,842
12,644
14,906
14,825
16,731
14,478
15,917
18,702
9,221
9,450
8,437
9,684
10,079
10,904
12,501
12,882
13,229
18,404
18,414
17,879
17,616
17,652
17,559
18,295
13,923
14,427
14,486
14,988
9,773
8,404
8,539
8,315
8,354
9,488
5,870
4,921
6,971
7,420
11,852
12,796
11,399
10,538
10,727
10,72710,53811,39912,79611,8527,4206,9714,9215,8709,4888,3548,3158,5398,4049,77314,98814,48614,42713,92318,29517,55917,65217,61617,87918,41418,40413,22912,88212,50110,90410,0799,6848,4379,4509,22118,70215,91714,47816,73114,82514,90612,6447,84216,68417,61315,35512,40410,9577,8216,44315,61214,64013,2239,6177,2297,1128,1836,6336,4766,8927,1356,9977,3207,3088,0705,5935,5986,5866,5865,7365,2006,4837,0814,6643,2623,2353,2673,2063,3133,3224,4844,2112,4202,2112,9122,7061,9011,8971,8311,5171,5421,570
       Short-term Debt 
0
116
115
676
683
694
1,048
410
417
426
566
717
847
886
958
938
856
773
689
952
960
928
886
999
999
771
692
721
601
483
370
2,047
2,497
2,564
2,634
2,705
2,778
1,978
4,211
6,453
8,724
8,755
69
2,487
4,911
7,338
9,767
9,784
9,800
21
1,193
3,191
5,241
7,342
5,477
7,363
10,000
26
1,446
1,750
1,724
3,494
5,267
6,629
6,686
6,744
13,497
13,624
13,729
13,836
14,007
14,202
15,071
10,970
11,093
11,327
11,318
6,165
6,321
6,468
6,599
6,745
6,858
1,719
1,718
1,712
1,715
1,718
5,164
4,819
4,465
4,096
4,0964,4654,8195,1641,7181,7151,7121,7181,7196,8586,7456,5996,4686,3216,16511,31811,32711,09310,97015,07114,20214,00713,83613,72913,62413,4976,7446,6866,6295,2673,4941,7241,7501,4462610,0007,3635,4777,3425,2413,1911,193219,8009,7849,7677,3384,9112,487698,7558,7246,4534,2111,9782,7782,7052,6342,5642,4972,0473704836017216927719999998869289609526897738569389588868477175664264174101,0486946836761151160
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13,836
14,007
14,202
14,371
10,813
10,937
11,060
11,182
6,026
6,181
6,335
6,486
6,618
6,752
1,608
1,608
1,608
1,608
1,608
5,057
4,709
4,348
3,976
3,9764,3484,7095,0571,6081,6081,6081,6081,6086,7526,6186,4866,3356,1816,02611,18211,06010,93710,81314,37114,20214,00713,836000000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
0
-1,166
-1,090
-900,676
-944
-1,444
-1,723
-19,410
-439
-448
0
0
0
-944
-2,458
2,329
2,379
2,489
535
6,129
5,523
4,272
359
0
729
4,827
4,901
479
6,707
6,837
6,627
464
-16,474
-9,224
-9,224
1,145
-5,512
-5,512
-5,512
-5,512,000
-13,005
-4,281
-4,281
272
-3,520
-1,107
-5,286
1,579
5,768
-228,748
0
965
-199,557
-205,473
-162,261
949
5,496
6,750
6,136
1,009
6,592
-106
-97
1,332
-109
-110
-103
1,297
-178
-217
-187
720
2,382
2,953
3,334
327
3,670
3,608
2,044
789
1,716
1,609
2,630
2,611
3,203
5,259
5,705
8,364
6,495
6,580
6,073
4,758
4,7586,0736,5806,4958,3645,7055,2593,2032,6112,6301,6091,7167892,0443,6083,6703273,3342,9532,382720-187-217-1781,297-103-110-1091,332-97-1066,5921,0096,1366,7505,496949-162,261-205,473-199,5579650-228,7485,7681,579-5,286-1,107-3,520272-4,281-4,281-13,005-5,512,000-5,512-5,512-5,5121,145-9,224-9,224-16,4744646,6276,8376,7074794,9014,82772903594,2725,5236,1295352,4892,3792,329-2,458-944000-448-439-19,410-1,723-1,444-944-900,676-1,090-1,1660
       Other Current Liabilities 
1,570
1,542
1,517
1,831
1,333
1,901
2,706
2,912
2,211
2,420
3,645
3,767
2,475
3,313
3,206
-1,500,000
-1,500
-1,500
1,940
-2,592,000
-29,128
-29,128
-24,637
0
-23,901,142
-22,110
-18,748
-18,741,130
0
0
0
-16,469,376
4,395
3,912
3,999
-7,629,667
4,334
5,251
5,406
6,770
14,640
6,857
6,374
-3,514,938
6,046
5,066
9,767
6,215
884
1,569
11,451
10,612
3,141
2,862
3,262
7,414
3,088
2,192
1,725
5,457
1,267
6,585
5,637
4,325
6,196
6,485
4,907
3,399
4,150
3,780
3,645
2,470
700
2,953
3,334
6
3,670
3,608
2,083
23
1,716
1,609
2,630
122
3,203
5,259
5,705
1,770
1,137
6,580
6,073
1,873
1,8736,0736,5801,1371,7705,7055,2593,2031222,6301,6091,716232,0833,6083,67063,3342,9537002,4703,6453,7804,1503,3994,9076,4856,1964,3255,6376,5851,2675,4571,7252,1923,0887,4143,2622,8623,14110,61211,4511,5698846,2159,7675,0666,046-3,514,9386,3746,85714,6406,7705,4065,2514,334-7,629,6673,9993,9124,395-16,469,376000-18,741,130-18,748-22,110-23,901,1420-24,637-29,128-29,128-2,592,0001,940-1,500-1,500-1,500,0003,2063,3132,4753,7673,6452,4202,2112,9122,7061,9011,3331,8311,5171,5421,570
   > Long-term Liabilities 
1,350
1,247
1,142
2,826
2,627
2,375
9,972
10,412
9,929
9,401
9,072
8,696
8,833
15,035
9,633
9,370
9,209
17,109
12,211
27,314
38,501
35,731
35,078
0
29,095
26,713
23,118
22,837
22,136
21,808
21,984
26,191
26,489
20,086
19,791
20,224
15,595
29,157
29,242
30,251
30,245
23,003
37,199
33,767
31,295
27,552
26,387
19,182
14,314
30,659
25,766
24,022
22,195
20,326
21,129
28,504
41,539
35,043
27,996
17,055
15,488
13,880
12,268
11,122
9,526
8,017
223
201
283
310
1,742
1,207
2,464
1,237
11,128
7,583
5,894
831
628
535
508
535
507
5,275
4,953
4,621
4,280
5,570
166
136
118
2,009
2,0091181361665,5704,2804,6214,9535,2755075355085356288315,8947,58311,1281,2372,4641,2071,7423102832012238,0179,52611,12212,26813,88015,48817,05527,99635,04341,53928,50421,12920,32622,19524,02225,76630,65914,31419,18226,38727,55231,29533,76737,19923,00330,24530,25129,24229,15715,59520,22419,79120,08626,48926,19121,98421,80822,13622,83723,11826,71329,095035,07835,73138,50127,31412,21117,1099,2099,3709,63315,0358,8338,6969,0729,4019,92910,4129,9722,3752,6272,8261,1421,2471,350
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
23,100
21,325
19,501
20,332
18,041
15,677
16,184
14,978
16,681
15,198
13,663
12,130
0
0
0
0
0
0
0
0
0
84
54
38
8
4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000004838548400000000012,13013,66315,19816,68114,97816,18415,67718,04120,33219,50121,32523,100000000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
310
1,742
1,207
862
435
10,406
6,929
5,266
242
83
7
5
5
3
1
0
0
0
1,643
0
0
0
0
00001,64300013557832425,2666,92910,4064358621,2071,742310000000000000000000000000000000000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
217
138
0
0
0
0
0
0
0
0
124
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000124000000001382170000000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
48,440
44,465
41,904
38,486
35,248
31,756
27,576
25,995
22,692
20,799
18,969
14,909
16,395
12,617
17,163
12,833
8,307
6,042
4,282
-6,229
-12,389
-18,497
-9,959
0
-10,813
4,500
238
-9,400
-11,064
-12,198
-2,313
-7,717
-5,723
-880
-1,423
-3,658
12,738
14,100
4,518
22,873
12,356
10,141
11,926
9,946
6,850
548
-9,732
6,455
2,368
1,263
-3,188
3,132
2,402
1,193
-3,293
-5,702
-23,195
2,260
5,000
12,206
7,743
18,721
13,670
10,986
7,363
11,230
7,819
13,000
8,480
4,751
6,138
5,225
3,857
-6,276
160
1,160
85
3,300
2,621
3,031
9,513
11,945
14,755
10,836
14,642
9,679
11,404
6,445
2,676
2,662
2,622
-1,348
-1,3482,6222,6622,6766,44511,4049,67914,64210,83614,75511,9459,5133,0312,6213,300851,160160-6,2763,8575,2256,1384,7518,48013,0007,81911,2307,36310,98613,67018,7217,74312,2065,0002,260-23,195-5,702-3,2931,1932,4023,132-3,1881,2632,3686,455-9,7325486,8509,94611,92610,14112,35622,8734,51814,10012,738-3,658-1,423-880-5,723-7,717-2,313-12,198-11,064-9,4002384,500-10,8130-9,959-18,497-12,389-6,2294,2826,0428,30712,83317,16312,61716,39514,90918,96920,79922,69225,99527,57631,75635,24838,48641,90444,46548,440
   Common Stock
20
15
15
15
15
15
15
17
17
17
17
17
17
17
17
17
17
18
18
18
18
18
21
0
22
26
26
26
27
28
31
31
34
36
38
40
44
46
46
52
52
52
55
57
58
59
59
66
67
67
67
71
75
79
83
99
114
151
159
195
13
20
20
22
24
33
35
58
62
62
67
15
22
0
3
4
4
4
5
7
10
12
15
16
22
22
32
34
36
3
5
5
553363432222216151210754443022156762625835332422202013195159151114998379757167676766595958575552525246464440383634313128272626262202118181818181717171717171717171715151515151520
   Retained Earnings -480,501-476,691-473,472-471,990-467,185-461,527-456,308-451,026-446,910-442,755-439,031-436,231-433,511-429,924-428,196-426,357-425,270-426,154-426,680-417,533-414,383-412,147-409,817-406,158-401,749-397,462-392,656-386,607-379,063-374,144-368,761-362,356-357,017-354,255-355,782-360,231-338,273-332,517-323,133-311,305-300,905-290,865-285,605-282,395-274,728-270,904-259,657-251,774-242,449-235,542-227,207-222,070-209,998-200,747-190,331-184,951-182,504-173,015-166,212-165,386-162,168-155,636-148,818-140,405-132,132-121,452-116,125-103,460-103,460-101,548-92,781-85,469-78,013-63,649-61,361-56,002-51,475-47,159-51,705-47,895-49,385-48,240-45,441-43,382-40,102-34,602-31,636-30,033-27,099-24,184-21,448-17,110
   Accumulated Other Comprehensive Income 
-5,100
259
451
350
49
178
186
159
118
107
63
26
17
-24
-15
-32
-32
-18
-23
-16
-71
-40
-34
-4,476
-14
-4,476
-4,476
-4
-4,955
-4,955
-4,955
-6,234
-6,234
0
0
-6,940
-6,940
0
0
-7,613
-7,613
0
0
-7,989
-7,989
0
0
-8,609
-110
-34
-142
256
206
399
457
700
736
951
1,061
996
747
617
675
1,258
1,198
1,183
1,199
1,387
1,106
1,237
1,182
1,218
1,078
0
0
-1,021
-1,021
0
0
-1,387
0
0
0
0
0
0
0
0
0
0
0
0
000000000000-1,38700-1,021-1,021001,0781,2181,1821,2371,1061,3871,1991,1831,1981,2586756177479961,061951736700457399206256-142-34-110-8,60900-7,989-7,98900-7,613-7,61300-6,940-6,94000-6,234-6,234-4,955-4,955-4,955-4-4,476-4,476-14-4,476-34-40-71-16-23-18-32-32-15-2417266310711815918617849350451259-5,100
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
303,710
313,426
323,848
328,684
331,772
336,186
356,940
358,035
368,032
369,339
386,845
387,119
0
0
0
0
0
0
0
0
418,375
420,290
420,404
426,311
426,426
426,438
431,492
432,540
436,535
445,734
450,964
0
0
0
0
0
0
0
0
0
0
0000000000450,964445,734436,535432,540431,492426,438426,426426,311420,404420,290418,37500000000387,119386,845369,339368,032358,035356,940336,186331,772328,684323,848313,426303,710000000000000000000000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
70,630
65,898
66,073
65,570
65,266
63,377
62,163
66,080
66,057
66,223
67,192
64,277
64,273
64,305
64,305
69,288
69,648
73,108
73,998
78,228
79,977
81,386
97,564
0
97,101
125,075
126,140
127,661
134,269
141,547
158,247
160,654
159,629
165,296
171,554
185,746
197,645
204,385
205,219
240,432
234,374
237,296
247,413
260,327
258,566
260,146
261,113
289,726
284,696
295,405
296,741
313,516
313,632
324,247
329,141
331,472
335,922
356,891
358,096
368,028
369,086
386,462
386,794
389,027
392,946
402,853
404,246
413,691
413,576
413,506
417,218
418,593
420,368
420,404
426,311
427,447
426,438
431,492
432,540
437,922
445,734
450,964
457,495
457,730
465,646
465,965
472,899
473,596
474,630
476,131
479,308
479,148
479,148479,308476,131474,630473,596472,899465,965465,646457,730457,495450,964445,734437,922432,540431,492426,438427,447426,311420,404420,368418,593417,218413,506413,576413,691404,246402,853392,946389,027386,794386,462369,086368,028358,096356,891335,922331,472329,141324,247313,632313,516296,741295,405284,696289,726261,113260,146258,566260,327247,413237,296234,374240,432205,219204,385197,645185,746171,554165,296159,629160,654158,247141,547134,269127,661126,140125,07597,101097,56481,38679,97778,22873,99873,10869,64869,28864,30564,30564,27364,27767,19266,22366,05766,08062,16363,37765,26665,57066,07365,89870,630



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue4,913
Cost of Revenue-745
Gross Profit4,1684,168
 
Operating Income (+$)
Gross Profit4,168
Operating Expense-17,489
Operating Income-13,321-13,321
 
Operating Expense (+$)
Research Development9,690
Selling General Administrative8,544
Selling And Marketing Expenses0
Operating Expense17,48918,234
 
Net Interest Income (+$)
Interest Income400
Interest Expense-395
Other Finance Cost-0
Net Interest Income5
 
Pretax Income (+$)
Operating Income-13,321
Net Interest Income5
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-13,316-13,326
EBIT - interestExpense = -13,716
-13,316
-12,921
Interest Expense395
Earnings Before Interest and Taxes (EBIT)-13,321-12,921
Earnings Before Interest and Taxes (EBITDA)-12,576
 
After tax Income (+$)
Income Before Tax-13,316
Tax Provision-0
Net Income From Continuing Ops-13,316-13,316
Net Income-13,316
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses18,234
Total Other Income/Expenses Net5-5
 

Technical Analysis of Plus Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Plus Therapeutics Inc. The general trend of Plus Therapeutics Inc is BEARISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Plus Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-71.4%) Bearish trend (71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Plus Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 1.76 < 2.09 < 2.26.

The bearish price targets are: 1.61 > 1.5978 > 1.37.

Tweet this
Plus Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Plus Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 2/14.
The longshort score for the Moving Averages is -10/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Plus Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Plus Therapeutics Inc. The current macd is -0.00996617.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Plus Therapeutics Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Plus Therapeutics Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Plus Therapeutics Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Plus Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartPlus Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Plus Therapeutics Inc. The current adx is 12.24.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Plus Therapeutics Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Plus Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Plus Therapeutics Inc. The current sar is 1.67125444.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Plus Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Plus Therapeutics Inc. The current rsi is 41.16. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Plus Therapeutics Inc Daily Relative Strength Index (RSI) ChartPlus Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Plus Therapeutics Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Plus Therapeutics Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Plus Therapeutics Inc Daily Stochastic Oscillator ChartPlus Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Plus Therapeutics Inc. The current cci is -95.30491554.

Plus Therapeutics Inc Daily Commodity Channel Index (CCI) ChartPlus Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Plus Therapeutics Inc. The current cmo is -29.419047.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Plus Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartPlus Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Plus Therapeutics Inc. The current willr is -97.22222222.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Plus Therapeutics Inc Daily Williams %R ChartPlus Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Plus Therapeutics Inc.

Plus Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Plus Therapeutics Inc. The current atr is 0.13023731.

Plus Therapeutics Inc Daily Average True Range (ATR) ChartPlus Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Plus Therapeutics Inc. The current obv is 33,200,040.

Plus Therapeutics Inc Daily On-Balance Volume (OBV) ChartPlus Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Plus Therapeutics Inc. The current mfi is 40.44.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Plus Therapeutics Inc Daily Money Flow Index (MFI) ChartPlus Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Plus Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-24SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-11-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-27WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-24MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-31CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-15CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-23CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-26SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-01CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-06STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-03SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-09CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.

6.3. Candlestick Patterns

Plus Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Plus Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5041.164
Ma 20Greater thanMa 501.849
Ma 50Greater thanMa 1001.885
Ma 100Greater thanMa 2001.915
OpenGreater thanClose1.820
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Plus Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Plus Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Plus Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Plus Therapeutics Inc

I send you an email if I find something interesting about Plus Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Plus Therapeutics Inc.

Receive notifications about Plus Therapeutics Inc in your mailbox!